[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530145":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":61,"collaborators":63,"id":66,"slug":17,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":17,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":17,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":44,"whyStopped":17,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"APG-2575","EXPERIMENTAL","Dose escalation",[13],"Drug: APG-2575",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",null,[19],"Other: Placebo",[21,25],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":17},"DRUG","Take orally once daily (QD) for 12 weeks.",[9],{"type":26,"name":15,"description":23,"armGroupLabels":27,"otherNames":17},"OTHER",[15],[29],{"name":30,"affiliation":31,"role":32},"Sheng Chen, Ph.D","Renji Hospital Shanghai Jiaotong University School of Medical","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":17,"email":38},"Yifan Zhai","CONTACT","240-505-6608","Yzhai@ascentage.com",{"name":40,"role":36,"phone":17,"phoneExt":17,"email":41},"Xiaofeng Han","Xiaofeng.Han@ascentage.com",[43],{"facility":31,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Shanghai","Shanghai Municipality","200127","China",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56,59],{"name":30,"role":36,"phone":57,"phoneExt":17,"email":58},"13917556052","13917556052@139.com",{"name":60,"role":32,"phone":17,"phoneExt":17,"email":17},"Sheng Chen, Ph.D.",{"type":62,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR",[64],{"name":65,"class":6},"Suzhou Yasheng Pharmaceutical Co., Ltd.","100530145",false,"NCT06182969","A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.","A Randomized, Double-blind, Placebo-controlled Phase I\u002FII Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.","Inclusion Criteria:\n\n* 1\\. Diagnosis of systemic lupus erythematosus for at least 6 months.\n* 2\\. On stable treatment for systemic lupus erythematosus before first dose at least 28 days.\n* 3\\. SLEDIA-2000 score: 4-12\n* 4.Other than systemic lupus erythematosus, subject should be in general good health.\n\nExclusion Criteria:\n\n* 1\\. Severe systemic lupus erythematosus.\n* 2\\. Significant autoimmune disease other than lupus.\n* 3\\. Significant, uncontrolled or unstable disease in any organ.","FEMALE","18 Years","65 Years",{"count":76,"type":77},40,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE1","PHASE2","To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).",[84],"SLE",[84,9],"2025-12-14",{"date":88,"type":89},"2025-12-16","ACTUAL",{"date":91,"type":89},"2024-08-09",{"date":93,"type":77},"2026-12",{"name":5,"class":6},1]